Immunonutrition Supplement Tested During Cancer Treatment in Head, Neck, Lung, and Rectal Cancer
Tests a nutrition supplement in adults with head, neck, lung, or rectal cancer during treatment.
Plain-language title generated from the registry record
Registry title: Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients
Key facts
- Where
- Candiolo, ItalySee the site
Where in Italy
- Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo, Candiolo, Turin 10060Candiolo, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione del Piemonte per l'Oncologia
- Trial code
- NCT07514754
- Record updated
- 7 April 2026
- Original description
GALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment. The study aims to assess whether the formula may reduce treatment-related toxicity and improve treatment compliance, using patients from the GALENOS 1 observational study as the control group for comparisonRead full original descriptionShow less
Use of an Immunonutrition Galenic Formulation in Head and Neck, Lung and Rectal Cancer Patients During Antineoplastic Treatments: A Prospective Study
GALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment. The study aims to assess whether the formula may reduce treatment-related toxicity and improve treatment compliance, using patients from the GALENOS 1 observational study as the control group for comparison
Inclusion: Written informed consent to study procedures; Male or female, age greater than 18 years; Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer candidate for immunotherapy, chemotherapy, and/or radiotherapy according to standard clinical practice; ECOG Performance Status score less than 2; Adequate kidney, liver, and bone marrow function; Ability to understand, sign informed consent, and comply with study procedures.
Exclusion: Incomplete recovery from surgery before starting antineoplastic treatment; Receipt of any live vaccine within 30 days before study treatment; Other progressing malignancy or malignancy requiring active treatment within the last 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ; Active infection requiring systemic antibiotic therapy; Serious or unstable medical conditions, psychiatric disorders, or substance abuse interfering with study compliance; Active cardiac pacing/pacing implants/neurostimulators/hearing system not compatible with bioimpedance analysis; Edema and/or ascites not compatible with body weight evaluation and bioimpedance analysis; Enteral or parenteral nutritional support at baseline.